{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gristina V"],"funding":["Piano Nazionale di Ripresa e Resilienza (PNRR) project - Italian Network of excellence for advanced diagnosis (INNOVA)"],"pagination":["1422-1435"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12077285"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(5)"],"pubmed_abstract":["Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non-small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum-based chemotherapy ± pembrolizumab were enrolled. EVs were characterized using Bradford assay to quantify the circulating cell-free EV protein content (cfEV), and dynamic light scattering to assess Rayleigh ratio excess at 90°, z-averaged hydrodynamic diameter and polydispersity index. A total of 135 plasma samples from 27 patients were collected at baseline (T0) and at the first radiological restaging (T1). A ∆cfEV < 20% was associated with improved median progression-free survival (mPFS) in responders versus non-responders. Specifically, cfEV responders on pembroli"],"journal":["Molecular oncology"],"pubmed_title":["On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study."],"pmcid":["PMC12077285"],"funding_grant_id":["PNC-E3-2022-23683266 PNC-HLS-DA (C43C22001630001)"],"pubmed_authors":["Bazan Russo TD","Taverna S","Carreca AP","Troncone G","Santini D","Galvano A","Manno M","Bono M","Raccosta S","Barraco N","Pepe F","Badalamenti G","Bazan V","Incorvaia L","Malapelle U","Pisapia P","Russo A","Gristina V"],"additional_accession":[]},"is_claimable":false,"name":"On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study.","description":"Extracellular vesicle (EV) monitoring can complement clinical assessment of cancer response. In this study, patients with advanced non-small cell lung cancer (NSCLC) undergoing osimertinib, alectinib, pembrolizumab or platinum-based chemotherapy ± pembrolizumab were enrolled. EVs were characterized using Bradford assay to quantify the circulating cell-free EV protein content (cfEV), and dynamic light scattering to assess Rayleigh ratio excess at 90°, z-averaged hydrodynamic diameter and polydispersity index. A total of 135 plasma samples from 27 patients were collected at baseline (T0) and at the first radiological restaging (T1). A ∆cfEV < 20% was associated with improved median progression-free survival (mPFS) in responders versus non-responders. Specifically, cfEV responders on pembroli","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-07-15T08:30:02.995Z","creation":"2026-07-01T03:11:58.785Z"},"accession":"S-EPMC12077285","cross_references":{"pubmed":["39780749"],"doi":["10.1002/1878-0261.13737"]}}